Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

1069 - Anti-interleukin-6 receptor antibody suppressed oral squamous cell carcinoma by inhibiting tumor-stroma interaction

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Hiroyuki Goda

Citation

Annals of Oncology (2015) 26 (suppl_9): 1-7. 10.1093/annonc/mdv517

Authors

H. Goda1, M. Okamoto2, K. Nakashiro1, N. Tokuzen1, H. Hamakawa1

Author affiliations

  • 1 Department Of Oral And Maxillofacial Surgery, Ehime University Graduate School of Medicine, 791-0295 - Toon/JP
  • 2 Department Of Advanced Immunotherapeutics, Kitasato University School of Pharmacy, Tokyo/JP
More

Resources

Abstract 1069

Aim/Background

Recent studies show that interleukin-6 (IL-6) plays an important role in cancer development and cancer stromal fibroblasts are necessary for steps in progression, such as angiogenesis. However, little is known about the prognostic significance of IL-6 to the biology and the carcinogenic potential of stromal fibroblasts for oral squamous cell carcinoma (OSCC). This study aimed to investigate the correlation between IL-6 and cancer stromal fibroblasts related angiogenesis and the utility of IL-6 as a therapeutic target in OSCC.

Methods

We evaluated expression levels of IL-6 in 53 OSCC tissues by immunohistochemical staining and established three pairs of normal fibroblast (NF) and cancer-associated fibroblast (CAF) cultures from OSCC surgical specimens and the normal counterparts. The expression levels of IL-6 and VEGF of NF and CAF were evaluated using quantitative RT-PCR and ELISA. We investigated the effect of an anti-human/anti-mouse IL-6 receptor antibody on the growth of OSCC cell line in vitro and vivo.

Results

Serial immunohistochemical staining of OSCC specimens showed that the IL-6 was mainly limited to cancer stromal region. NF cells were positive for vimentin and negative for cytokeratin AE1/AE3 and α-SMA. CAF cells were vimentin and α-SMA positive and cytokeratin AE1/AE3 negative. We confirmed that CAF produced significant amounts of IL-6 and VEGF than NF. Moreover, IL-6 enhanced VEGF production in NF and CAF, thereby inducing angiogenesis. We examined the in vitro cell proliferation of OSCC cells and CAF cells by WST-8 assay. Neither humanized anti-IL-6 receptor monoclonal antibody nor exogenous IL-6 influenced the proliferation rate of SAS cells and CAF cells under condition of single culture. However, in vivo study the IL-6 antibody reduced tumor volume by 70%.

Conclusions

These data suggest that inhibition of the relationship between IL-6 and stromal fibroblasts offers new approaches to OSCC therapy.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings